Nestle proposes new CEO
This article was originally published in The Tan Sheet
Executive Summary
Nestle's board of directors proposes Paul Bulcke, a member of Nestle's executive board and head of Zone Americas, take on the role of CEO at the firm's next annual board meeting April 10, 2008. Current CEO Peter Brabeck-Letmathe will serve as active, non-executive, chairman, Nestle said Sept. 20. The board cites the decision to separate the chairman and CEO positions, anticipating an increasing workload for the chairman's office, and the desire for management continuity by entrusting the CEO position to a younger person as reasons for appointing Bulcke. Bulcke's nomination took place under the leadership of the independent Compensation and Nomination Committee and was received unanimous approval by the board. Bulcke's successor at Zone Americas will be announced Oct. 18...
You may also be interested in...
Nestle sales
"Robust innovation and renovation pipeline" for infant formula contributed to 6.6% growth in Nestle Nutrition sales to 5.7 bil. Swiss Francs ($4.87 bil.) for the January-September period, company announces Oct. 18. For the nine-month period, organic sales advanced 9.7%, "in line with the business' long-term target of 10%," firm adds. "NAN premium starter formulas and Nestle infant cereals enriched with probiotics to strengthen infants' immune systems, did particularly well in their global rollout," according to Nestle. Firm's Powdered and Liquid Beverages unit achieved sales of 12.8 bil. Swiss Francs ($10.9 bil.), representing growth of 7.5%, or 10% organically. Nestle also announces promotion of Acquisitions and Business Development Chief Jim Singh to CFO, and Paul Polman as head of Zone Americas, replacing Paul Bulcke, who will assume the CEO post in the spring (1"The Tan Sheet" Oct. 1, 2007, In Brief)...
Can Organovo Leverage Its Solid Phase II Data In MASH?
Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.
Cullinan Changes Tracks, Moving Lymphoma Bispecific Into Autoimmune
The company will discontinue its trial of the CD19-directed bispecific CLN-978 in NHL and develop it in inflammatory diseases, where it could have an edge over CAR-Ts.